Jennison Associates LLC Reduces Position in Neurocrine Biosciences, Inc. (NBIX)
Jennison Associates LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 50.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 322,116 shares of the company’s stock after selling 328,256 shares during the period. Jennison Associates LLC owned approximately 0.37% of Neurocrine Biosciences worth $14,817,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Teacher Retirement System of Texas raised its position in shares of Neurocrine Biosciences by 0.8% in the second quarter. Teacher Retirement System of Texas now owns 6,966 shares of the company’s stock worth $320,000 after buying an additional 57 shares during the last quarter. Schroder Investment Management Group raised its position in shares of Neurocrine Biosciences by 1.7% in the first quarter. Schroder Investment Management Group now owns 20,496 shares of the company’s stock worth $856,000 after buying an additional 335 shares during the last quarter. First Mercantile Trust Co. raised its position in shares of Neurocrine Biosciences by 22.2% in the first quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after buying an additional 560 shares during the last quarter. Nuveen Asset Management LLC raised its position in shares of Neurocrine Biosciences by 5.6% in the first quarter. Nuveen Asset Management LLC now owns 14,464 shares of the company’s stock worth $626,000 after buying an additional 763 shares during the last quarter. Finally, Aperio Group LLC raised its position in shares of Neurocrine Biosciences by 3.7% in the second quarter. Aperio Group LLC now owns 22,324 shares of the company’s stock worth $1,027,000 after buying an additional 789 shares during the last quarter. 95.87% of the stock is owned by institutional investors.
Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at 52.83 on Friday. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $55.38. The firm’s 50-day moving average price is $50.23 and its 200 day moving average price is $47.62. The stock’s market capitalization is $4.66 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.01. The business had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same quarter in the previous year, the business posted ($0.46) EPS. On average, equities analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2017/08/27/jennison-associates-llc-reduces-position-in-neurocrine-biosciences-inc-nbix.html.
A number of brokerages recently commented on NBIX. Jefferies Group LLC increased their price target on Neurocrine Biosciences from $65.00 to $67.00 and gave the company a “buy” rating in a research note on Monday, May 1st. Cowen and Company reissued an “outperform” rating and set a $65.00 price target (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price target (down from $62.00) on shares of Neurocrine Biosciences in a research note on Wednesday, May 24th. Leerink Swann dropped their price target on Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, May 25th. Finally, Bank of America Corporation began coverage on Neurocrine Biosciences in a research note on Friday, May 5th. They set a “buy” rating and a $70.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have assigned a buy rating to the stock. Neurocrine Biosciences presently has a consensus rating of “Buy” and an average target price of $68.25.
In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 8,734 shares of Neurocrine Biosciences stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $436,700.00. Following the transaction, the insider now owns 57,707 shares in the company, valued at approximately $2,885,350. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Haig P. Bozigian sold 22,500 shares of Neurocrine Biosciences stock in a transaction on Friday, August 4th. The shares were sold at an average price of $50.00, for a total transaction of $1,125,000.00. Following the completion of the transaction, the insider now owns 154,601 shares in the company, valued at approximately $7,730,050. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,588 shares of company stock worth $2,406,170. 4.80% of the stock is owned by company insiders.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.